07.06.2013 | Pharmacogenomics, 2013

Pharmacogenomics , June 2013, Vol. 14, No. 8, Pages 853-856.

mehr

07.06.2013 | Huizhe Wu; Hui Kang; Yong Liu; Qinghuan Xiao; Yining Zhang; Mingjun Sun; Duo Liu; Zhe Wang; Haishan ..., Pharmacogenomics, 2013

Aim: To evaluate the association of ABCB1 gene polymorphisms with susceptibility to colorectal cancer (CRC) and clinical outcomes of CRC patients with chemotherapy. Patients & methods: A case–control study was performed on the C3435T, C1236T and G2677T/A polymorphisms in the ABCB1 gene in ...

mehr

07.06.2013 | Andrzej Pawlik; Marek Drozdzik, Pharmacogenomics, 2013

Pharmacogenomics , June 2013, Vol. 14, No. 8, Pages 857-860.

mehr

07.06.2013 | Talitha I Verhoef; William K Redekop; David L Veenstra; Rahber Thariani; Peter A Beltman; Rianne MF van ..., Pharmacogenomics, 2013

Aim: To investigate the cost–effectiveness of pharmacogenetic-guided phenprocoumon dosing versus standard anticoagulation care in Dutch patients with atrial fibrillation. Materials & methods: Using a decision-analytic Markov model, cost–effectiveness of pharmacogenetic-guided therapy versus ...

mehr

07.06.2013 | Kijoung Song; Michael Mosteller; Michael Lawson; Matthew R Nelson, Pharmacogenomics, 2013

Pharmacogenomics , June 2013, Vol. 14, No. 8, Pages 851-852.

mehr

07.06.2013 | Sabrina Angelini; Gloria Ravegnini; Jonathan A Fletcher; Francesca Maffei; Patrizia Hrelia, Pharmacogenomics, 2013

Gastrointestinal stromal tumor (GIST) is a well-recognized and now relatively well-understood mesenchymal tumor. Before the imatinib era, the treatment of metastatic GIST was frustrating owing to its refractoriness to conventional chemotherapy and radiotherapy. After a metastatic GIST patient ...

mehr

07.06.2013 | Pharmacogenomics, 2013

Pharmacogenomics , June 2013, Vol. 14, No. 8, Pages 997-997.

mehr

07.06.2013 | Miao Hu; Brian Tomlinson, Pharmacogenomics, 2013

Statins are the most widely used group of lipid-lowering drugs and they have been shown to be effective in the prevention of cardiovascular disease, primarily by reducing plasma low-density lipoprotein cholesterol concentrations and possibly through other pleiotropic effects. However, there ...

mehr

07.06.2013 | Rachel Mills; Susanne B Haga, Pharmacogenomics, 2013

One of the basic questions in the early uses of pharmacogenetic (PGx) testing revolves around the clinical delivery of testing. Because multiple health professionals may play a role in the delivery of PGx testing, various clinical delivery models have begun to be studied. We propose that a ...

mehr

07.06.2013 | Greyson P Twist; Roger Gaedigk; J Steven Leeder; Andrea Gaedigk, Pharmacogenomics, 2013

High-resolution melt (HRM) analysis using ‘release-on-demand’ dyes, such as EvaGreen® has the potential to resolve complex genotypes in situations where genotype interpretation is complicated by the presence of pseudogenes or allelic variants in close proximity to the locus of interest. We ...

mehr